カレントテラピー 31-6 サンプル

カレントテラピー 31-6 サンプル page 16/32

電子ブックを開く

このページは カレントテラピー 31-6 サンプル の電子ブックに掲載されている16ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要:
カレントテラピー 31-6 サンプル

46 Current Therapy 2013 Vol.31 No.6604terminal renal failure in proteinuric, non-diabetic nephropathy.Lancet 349:1857-1863, 19974)Go AS, Chertow GM, Fan D, et al:Chronic kidney diseaseand the risks of death, cardiovascular events, and hospitalization.N Engl J Med 351:1296-1305, 20045)Sarnak MJ, Levey AS, Schoolwerth AC, et al;AmericanHeart Association Councils on Kidney in Cardiovascular Disease,High Blood Pressure Research, Clinical Cardiology, andEpidemiology and Prevention:Kidney disease as a risk factorfor development of cardiovascular disease:a statementfrom the American Heart Association Councils on Kidney inCardiovascular Disease, High Blood Pressure Research, ClinicalCardiology, and Epidemiology and Prevention. Circulation108:2154-2169, 20036)Keith DS, Nichols GA, Gullion CM, et al:Longitudinal followupand outcomes among a population with chronic kidneydisease in a large managed care organization. Arch InternMed 164:659-663, 20047)Tokuyama H, Kelly DJ, Zhang Y, et al:Macrophage infiltrationand cellular proliferation in the non-ischemic kidney andheart following prolonged unilateral renal ischemia. NephronPhysiol 106:p54-p62, 20078)Tokuyama H, Hayashi K, Matsuda H, et al:Differential regulationof elevated renal angiotensin Ⅱ in chronic renal ischemia.Hypertension 40:34-40, 20029)Hayashi K, Wakino S, Homma K, et al:Pathophysiologicalsignificance of T-type Ca2+ channels:role of T-type Ca2+channels in renal microcirculation. J Pharmacol Sci 99:221-227, 200510)Matsushita K, van der Velde M, Astor BC, et al;ChronicKidney Disease Prognosis Consortium:Association of estimatedglomerular filtration rate and albuminuria with allcauseand cardiovascular mortality in general populationcohorts:a collaborative meta-analysis. Lancet 375:2073-2081, 201011)Levey AS, de Jong PE, Coresh J, et al:The definition, classification,and prognosis of chronic kidney disease;a KDIGOControversies Conference report. Kidney Int 80:17-28, 201112)Iseki K, Ikemiya Y, Kinjo K, et al:Body mass index and therisk of development of end-stage renal disease in a screenedcohort. Kidney Int 65:1870-1876, 200413)Levey AS, Greene T, Beck GJ, et al:Dietary protein restrictionand the progression of chronic renal disease:what haveall of the results of the MDRD study shown? Modification ofDiet in Renal Disease Study group. J Am Soc Nephrol 10:2426-2439, 199914)Agodoa LY, Appel L, Bakris GL, et al;African AmericanStudy of Kidney Disease and Hypertension(AASK)StudyGroup:Effect of ramipril vs amlodipine on renal outcomes inhypertensive nephrosclerosis:a randomized controlled trial.JAMA 285:2719-2728, 200115)Ruggenenti P, Perna A, Loriga G, et al;REIN -2 StudyGroup:Blood-pressure control for renoprotection in patientswith non-diabetic chronic renal disease(REIN -2):multicentre,randomized controlled trial. Lancet 365:939-946,200516)Lewis EJ, Hunsicker LG, Clarke WR, et al;Collaborativestudy Group:Renoprotective effect of the angiotensin -receptor antagonist irbesartan in patients with nephropathydue to type 2 diabetes. N Eng J Med 345:851-860, 200117)Hasebe N, Kikuchi K;NICE Combi Study Group:Controlled-release nifedipine and candesartan low-dose combinationtherapy in patients with essential hypertension:theNICE Combi(Nifedipine and Candesartan Combination)Study. J Hypertension 23:445-453, 200518)Hayashi K, Kumagai H, Saruta T:Effect of efonidipine andACE inhibitors on proteinuria in human hypertension withrenal impairment. Am J Hypertens 16:116-122, 200319)Fujita T, Ando K, Nishimura H, et al;Cilnidipine versusAmlodipine Randomised Trial for Evaluation in RenalDesease(CARTER)Study Investigators:Antiproteinuriceffect of the calcium channel blocker cilnidipine added torenin-angiotensin inhibition in hypertensive patients withchronic renal disease. Kidney Int 72:1543-1549, 200720)Sato A, Hayashi K, Naruse M, et al:Effectiveness of aldosteroneblockade in patients with diabetic nephropathy. Hypertension41:64-68, 2003